Company research
Lomond Therapeutics Holdings, Inc.
CIK 1900520Updated Sep 24, 2026
Name history
Venetian-1 Acquisition Corp. · through Oct 28, 2024
Filing activity
Latest filing
50 filings on record · 15-12G, S-8 POS, RW, 10-Q, 10-K, NT 10-K.
About the company
Lomond Therapeutics is a biopharmaceutical company co-founded by Orbimed, Torrey Pines Investment and Dr. John C. Byrd, focused on the discovery and development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic and solid cancers. The company is utilizing a proprietary hybrid AI platform of Expert Systems Inc., leveraging its key partners proprietary data, chem/bio tools, knowledge and expertise to choose highly valuable molecular mechanism of pathology, to rationally design, accelerate discovery and optimize development of best-in-class and first-in-class therapies. Lomond Therapeutics' goal is to utilize its capabilities and platform to become a leader in developing novel breakthrough medicines to maximize the clinical benefit when treating hematologic and solid malignancies. For more information visit www.lomondther.com.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 30,819,674Source | 29,251,789Source | 984Source | 107Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 13,202,359Source | 28,400,000Source | — | — |
| Assets, CurrentUSD | 27,266,097Source | 29,251,789Source | 984Source | 107Source |
| Prepaid Expense and Other Assets, CurrentUSD | 967,350Source | 834,479Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 9,508,490Source | 5,496,524Source | 103,200Source | 54,387Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 3,220Source | 2,720Source | 500Source | 500Source |
| Additional Paid in CapitalUSD | 87,957,563Source | 66,630,765Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -62,344,503Source | -38,813,124Source | -102,716Source | -54,780Source |
| Stockholders' Equity Attributable to ParentUSD | 21,311,184Source | 23,755,265Source | -102,216Source | -54,280Source |
| Liabilities and EquityUSD | 30,819,674Source | 29,251,789Source | 984Source | 107Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,508,490Source | 2,554,256Source | 103,200Source | — |
| Accounts Payable, CurrentUSD | 3,910,459Source | — | — | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 24,400,000Source | — | — | — |
| Short-term InvestmentsUSD | 11,237,595Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,833,298Source | 472,263Source | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 3,649,846Source | 260,613Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -22,781,644Source | -12,041,057Source | -46,503Source | -45,102Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -10,927,307Source | — | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 18,494,000Source | 39,657,639Source | 47,380Source | 35,120Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | -9,982Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 13,202,359Source | 28,417,310Source | 984Source | 107Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 24,400,000Source | — | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | 833,328Source | — | — |
| General and Administrative ExpenseUSD | 4,200,525Source | 1,941,963Source | 47,936Source | 48,869Source |
| Investment Income, InterestUSD | 1,183,374Source | 137,426Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -23,531,379Source | -17,087,453Source | -47,936Source | -48,869Source |
| Nonoperating Income (Expense)USD | 927,607Source | 800,000Source | — | — |
| Operating ExpensesUSD | 24,458,986Source | 16,280,018Source | — | — |
| Proceeds from Contributed CapitalUSD | — | 7,450,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | 20,000,000Source | 32,965,500Source | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 310,288Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -24,458,986Source | -16,280,018Source | -47,936Source | -48,869Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 23,531,379Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -23,531,379Source | -17,087,453Source | -47,936Source | -48,869Source |
| Earnings Per Share, BasicUSD per share | -0.75Source | -3.3Source | -0.01Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | -0.75Source | -3.3Source | -0.01Source | -0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 31,479,036Source | 5,177,582Source | 5,000,000Source | 5,000,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 31,479,036Source | 5,177,582Source | 5,000,000Source | 5,000,000Source |
| Additional Financial Items | ||||
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | 833,328Source | — | — |
| General and Administrative ExpenseUSD | 4,200,525Source | 1,941,963Source | 47,936Source | 48,869Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 11,268,327Source | — | — | — |
| Interest Expense, DebtUSD | — | 42,268Source | — | — |
| Investment Income, InterestUSD | 1,183,374Source | 137,426Source | — | — |
| Nonoperating Income (Expense)USD | 927,607Source | 800,000Source | — | — |
| Operating ExpensesUSD | 24,458,986Source | 16,280,018Source | — | — |
| Other ExpensesUSD | — | 69,265Source | — | — |
| Research and Development ExpenseUSD | 20,258,461Source | 14,338,055Source | — | — |
Offerings
Registration 333-283508
Filing attachments
ea024630301ex99-1_lomond.htm · 8-K · 2025-06-20
EX-99.1 2 ea024630301ex99-1_lomond.htm PRESS RELEASE, DATED JUNE 20, 2025 Exhibit 99.1 LOMOND THERAPEUTICS ANNOUNCES U.S FDA CLEARANCE OF IND APPLICATION FOR LONITOCLAX, A SELECTIVE BCL2 INHIBITOR WITH LIMITED IMMUNE SUPPRESSION AND IMPROVED SAFETY COMPARED TO VENETOCLAX AND VENETOCLAX- LIKE MOLECULES DOVER, Del., June 20, 2025 -- Lomond Therapeutics Holdings, Inc. (“Lomond Therapeutics”), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-cl…
Read attachment ↗ea023580901ex99-1_lomond.htm · 8-K · 2025-03-28
EX-99.1 3 ea023580901ex99-1_lomond.htm PRESS RELEASE, DATED MARCH 28, 2025 Exhibit 99.1 Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors Dover, DEL. March 28, 2025. Lomond Therapeutics Holdings, Inc. (“Lomond Therapeutics”), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, today announced the addition of two new investors, Y…
Read attachment ↗